Jazz Pharmaceuticals (JAZZ) Operating Expenses (2010 - 2026)

Jazz Pharmaceuticals has reported Operating Expenses for 17 years, with the latest figure at $732.3 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Expenses fell 23.21% year-over-year to $732.3 million; the trailing twelve-month figure through Mar 2026 stood at $4.5 billion (up 28.99% YoY), and the FY2025 full-year result was $4.7 billion, up 40.14% from the prior year.
• Operating Expenses for Q1 2026 stood at $732.3 million, down from $943.4 million in the prior quarter.
• The five-year high for Operating Expenses was $1.7 billion in Q2 2025, with the low at $726.2 million in Q1 2022.
• Average Operating Expenses over 5 years is $927.2 million, with a median of $847.3 million recorded in 2022.
• Year-over-year, Operating Expenses declined 28.01% in 2023 and surged 110.11% in 2025.
• Tracing JAZZ's Operating Expenses over 5 years: stood at $1.2 billion in 2022, then decreased by 28.01% to $889.4 million in 2023, then increased by 0.9% to $897.4 million in 2024, then grew by 5.12% to $943.4 million in 2025, then dropped by 22.38% to $732.3 million in 2026.
• The last three Operating Expenses figures came in at $732.3 million (Q1 2026), $943.4 million (Q4 2025), and $1.1 billion (Q3 2025), per Business Quant data.

Peer Comparison